Diabetic Macular Edema (DME) Clinical Trials

Find Diabetic Macular Edema (DME) Clinical Trials Near You

A Randomized, Double-Masked, Multicenter, 3-Arm, Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) MK-8748 Compared With Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)

Status: Recruiting
Location: See all (19) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME. An available standard (usual) treatment for DME is aflibercept. However, standard treatments such as aflibercept may not work for every person. The main goal of this trial is to learn if MK-8748 works as well as aflibercept to treat DME.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

⁃ The main inclusion criteria include but are not limited to the following:

• Has Type 1 or Type 2 diabetes mellitus and a hemoglobin A1c (HbA1c) of ≤12%

• Has a decrease in vision in the study eye determined by the Investigator to be primarily the result of diabetic macular edema (DME)

• For participants who are treatment-naïve for DME, the diagnosis must have been made within 9 months of screening. For all treatment-experienced participants, the first treatment should have been no longer than 3 years prior to the Screening visit

Locations
United States
Connecticut
Retina Group of New England ( Site 0101)
RECRUITING
Waterford
Florida
Florida Retina Institute ( Site 0035)
RECRUITING
Orlando
Retina Vitreous Associates of Florida ( Site 0036)
RECRUITING
St. Petersburg
Center for Retina and Macular Disease ( Site 0047)
RECRUITING
Winter Haven
Iowa
Wolfe Eye Clinic ( Site 0044)
RECRUITING
West Des Moines
Indiana
Associated Vitreoretinal and Uveitis Consultants ( Site 0099)
RECRUITING
Carmel
Maryland
Cumberland Valley Retina Consultants ( Site 0003)
RECRUITING
Hagerstown
North Carolina
North Carolina Retina Associates ( Site 0122)
RECRUITING
Greenville
Graystone Eye ( Site 0059)
RECRUITING
Hickory
Piedmont Retina Specialists ( Site 0049)
RECRUITING
Winston-salem
New York
Retina-Vitreous Surgeons of Central NY ( Site 0021)
RECRUITING
Liverpool
South Carolina
Palmetto Retina Center ( Site 0073)
RECRUITING
Aiken
Charleston Neuroscience Institute ( Site 0090)
RECRUITING
Beaufort
Charleston Neuroscience Institute ( Site 0076)
RECRUITING
Charleston
Retina Consultants of South Carolina ( Site 0026)
RECRUITING
Ladson
Texas
Texas Retina ( Site 0051)
RECRUITING
Arlington
Texas Retina Associates ( Site 0055)
RECRUITING
Fort Worth
Retina Consultants of Texas - Katy/Cinco Ranch ( Site 0100)
RECRUITING
Katy
Retina Center of Texas ( Site 0096)
RECRUITING
Southlake
Contact Information
Primary
Toll Free Number
Trialsites@msd.com
1-888-577-8839
Time Frame
Start Date: 2026-09-25
Estimated Completion Date: 2029-11-30
Participants
Target number of participants: 1104
Treatments
Experimental: MK-8748 Low Dose
Participants receive 5 initial administrations of MK-8748 low dose every 4 weeks (Q4W), then continue to receive MK-8748 low dose every 8 weeks (Q8W) until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 100.
Experimental: MK-8748 High Dose
Participants receive 5 initial administrations of MK-8748 high dose every 4 weeks (Q4W), then continue to receive MK-8748 high dose every 8 weeks (Q8W) until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 100.
Active_comparator: Aflibercept 2 mg
Participants receive 5 initial administrations of aflibercept 2 mg every 4 weeks (Q4W), then continue to receive aflibercept 2mg every 8 weeks (Q8W) until week 100.
Sponsors
Leads: Merck Sharp & Dohme LLC

This content was sourced from clinicaltrials.gov